Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Up 128.0% in January

Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 1,220,000 shares, an increase of 128.0% from the January 15th total of 535,000 shares. Based on an average daily volume of 595,600 shares, the short-interest ratio is currently 2.0 days. Currently, 1.7% of the shares of the stock are sold short.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ:TLSA traded up $0.05 during trading hours on Friday, hitting $0.79. 348,594 shares of the company’s stock traded hands, compared to its average volume of 1,207,392. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74. The company’s fifty day simple moving average is $0.77 and its two-hundred day simple moving average is $0.92.

Hedge Funds Weigh In On Tiziana Life Sciences

Large investors have recently made changes to their positions in the business. Bison Wealth LLC bought a new position in shares of Tiziana Life Sciences during the 4th quarter valued at about $30,000. Zhang Financial LLC boosted its position in shares of Tiziana Life Sciences by 24.2% during the 3rd quarter. Zhang Financial LLC now owns 69,387 shares of the company’s stock valued at $67,000 after purchasing an additional 13,500 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Tiziana Life Sciences by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock valued at $171,000 after purchasing an additional 27,041 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Tiziana Life Sciences during the 3rd quarter valued at about $864,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.